Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance
JM Strizki, JM Gaspar, JA Howe… - Antimicrobial Agents …, 2024 - Am Soc Microbiol
Molnupiravir, an oral prodrug of N-hydroxycytidine (NHC), previously demonstrated broad in
vitro antiviral activity against multiple RNA viruses and has shown a high barrier to the …
vitro antiviral activity against multiple RNA viruses and has shown a high barrier to the …
[HTML][HTML] Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2
W Holman, W Holman, S McIntosh, W Painter… - Trials, 2021 - Springer
A recently published article described the safety, tolerability, and pharmacokinetic profile of
molnupiravir (Painter et al. 2021), a novel antiviral agent with potent activity against severe …
molnupiravir (Painter et al. 2021), a novel antiviral agent with potent activity against severe …
Drug treatments for covid-19: living systematic review and network meta-analysis
Objective To compare the effects of treatments for coronavirus disease 2019 (covid-19).
Design Living systematic review and network meta-analysis. Data sources WHO covid-19 …
Design Living systematic review and network meta-analysis. Data sources WHO covid-19 …
[HTML][HTML] Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis
T Pitre, R Van Alstine, G Chick, G Leung, D Mikhail… - Cmaj, 2022 - Can Med Assoc
Background: Randomized trial evidence suggests that some antiviral drugs are effective in
patients with COVID-19. However, the comparative effectiveness of antiviral drugs in …
patients with COVID-19. However, the comparative effectiveness of antiviral drugs in …